Elizabeth AllenResearch Associate II, Frontier Science Yanjie (Belle) BaoSenior Manager, Formulation Development James BarlowDirector of the Board Bio
Director of the Board
James Barlow is a member of the Board of Directors of NAHS Holding, Inc., an Employee Stock Ownership Plan company, whose affiliates provide post-acute care, subacute care, short and long-term rehabilitation, and skilled nursing in the United States. Mr. Barlow is a C-level financial executive with more than 30 years of experience leading teams in the successful strategic achievement of financial and operational goals, and expertise in domestic and international operations, financial planning, forecasting and reporting, restructurings, business development and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. from January 2002 to March 2015, he oversaw financial due diligence, integration and structuring for all significant asset purchases, sales, business combinations and licensing transactions, the spin-off of Advanced Medical Optics, the $3.3 billion acquisition of Inamed Corporation and more than $4.5 billion in other transactions. He ensured consistent application of corporate policies and procedures and alignment with global reporting and corporate compliance requirements, made recommendations globally to improve financial operations and participated in robust financial planning/forecasting activities. Prior to joining Allergan, Mr. Barlow served as Chief Financial Officer of Wynn Oil Company, a division of Parker Hannifin Corporation, during 2001, Treasurer and Controller of Wynn’s International, Inc. from 1990 to 2000 and Vice President and Controller of Ford Equipment Leasing Company from 1986 to 1990. From 1983 to 1985 Mr. Barlow worked for the accounting firm Deloitte Haskins and Sells. Mr. Barlow received a Bachelor of Science degree in Accounting, graduating magna cum laude, from Brigham Young University and a Master of Accountancy, graduating with honors - high distinction, from Brigham Young University. He is a certified public accountant (inactive).
Hari BhaskaranScientist II, RNA Sciences Whitney Bullard Scientist I, Translational Biology Arisa Iga CaleSr. Research Associate Giulio CattarossiSenior Research Associate, Translational Biology Lena CeballosPublic Relations & Marketing Specialist Brandon ChenAnalyst Investor Relations/Public Relations Pad ChivukulaCSO, COO Bio
Pad Chivukula, Ph.D., is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.
ThanhChau DamSr. Research Associate, Translational Biology Jared DavisVP, Technical Operations & Manufacturing Bio
VP, Technical Operations & Manufacturing
Jared Davis, Ph.D., has spent the last 18 years working in the RNA field designing, manufacturing, analyzing, and studying RNA. Jared has been an inventor on multiple patents regarding the design and manufacture of mRNA. Since Joining Arcturus Therapeutics in 2017, Jared has led the design and implementation of Arcturus’ proprietary mRNA manufacturing process. This process has been used to produce Arcturus’ Covid-19 vaccine and OTC mRNA for clinical trials. Prior to joining Arcturus, Jared led the synthetic process development group at Alexion pharmaceuticals. While at Alexion, he led internal and external CMC activities surrounding nucleic acid and small molecule programs. Jared received his Bachelor of Science in Biochemistry at Brigham Young University, his PhD in Biochemistry at the University of Wisconsin-Madison and did his postdoctoral research at Yale University.
Michael Delbuono Research Associate I, Analytical Development Peter FarrellChairman of the Board Bio
Chairman of the Board
Dr. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (NYSE:RMD). Farrell has been Chairman and a director of ResMed since 1989, when the company began as a management buyout of sleep technology from Baxter Healthcare. Peter was previously Foundation Director of the University of New South Wales (UNSW) Graduate School for Biomedical Engineering (1978-89) while simultaneously serving as Vice President of Research & Development for Baxter Healthcare in Tokyo (1984-89). He is also on the board of trustees of The Scripps Research Institute in La Jolla and is Chairman of the Boston-based POC NMR diagnostic company, WaveGuide. Dr. Farrell is a fellow or honorary fellow of several professional bodies, including the US National Academy of Engineering. He was inducted as 1998 San Diego Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year and 2005 US National Entrepreneur of the Year for Health Sciences. In 1998, Peter joined the Sleep Medicine Executive Council at Harvard Medical School, served as vice chairman from 2000 to 2010 and then as chairman from 2010 until 2013. He is on various academic advisory boards including UCSD's Jacobs School of Engineering, where he was named the 2012 Gordon Fellow, UCSD's Rady Business School and the MIT Dean of Engineering's Advisory Council. Peter holds a B.E. with honors in chemical engineering from the University of Sydney, an SM in chemical engineering from MIT, a PhD in bioengineering from the University of Washington, Seattle, and a DSc from UNSW for research which resulted in improved treatment for both hemodialysis and peritoneal dialysis patients.
Jose GonzalesSr. Research Associate Tamar Grossman Head of Rare Diseases Xuefeng Guo Scientist I, Analytical Development JP HeadleyAssociate Director, Accounting and Operations Michael HodgesR&D & Medical Consultant Bio
R&D & Medical Consultant
Michael R. Hodges, M.D., BSc. is an infectious disease clinician and RNA medicines drug development executive with 30 years of experience within the biopharmaceutical industry. He is currently Chief Medical Officer (CMO) at Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. Prior to Amplyx he was the CMO for two RNA platform companies, Santaris A/S and Altair Therapeutics Inc., developing drugs for infectious diseases, cancer, metabolic and respiratory diseases. Previously, he served in Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Dr. Hodges earned his M.D. (MBBS) and a BSc. In Pharmacology, from the University of London, UK.
Dr. Ed HolmesDirector of the Board Bio
Dr. Ed Holmes
Director of the Board
Dr. Holmes is currently a Distinguished Professor of Medicine at the University of California, Vice Chancellor/Dean of Health Sciences Emeritus at the University of California, San Diego, and CEO/President of the Sanford Consortium for Regenerative Medicine. He became the Executive Deputy Chairman of the Biomedical Research Council and the Executive Chairman of the National Medical Research Council in Singapore in October 2006; he is currently a Senior Fellow in A*STAR and Advisor to the National Research Council of Singapore. He holds an appointment as the Lien Ying Chow Professor of Medicine at the Yong Loo Lin School of Medicine, National University of Singapore. For his contributions to the Singapore government, Dr. Holmes was made an Honorary Citizen in 2011, and he was awarded the President’s Science and Technology Medal in 2017. Dr. Holmes also served on the Council of Advisors for the National Institute for Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health. He served as Chair of the Research Advisory Board of GlaxoSmithKline, the SAB of Ajinomoto and Board of Directors of Tularik, Inc. He also served on the Grand Challenges Explorations Innovation Review Panel for the Gates Foundation. He has been elected to membership in the American Society for Clinical Investigation, the Association of American Physicians, Fellow of the American Association for the Advancement of Science, and a member of the United States National Academy of Medicine.
Dr. Steve HughesChief Development Officer Bio
Dr. Steve Hughes
Chief Development Officer
Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at leading biopharma companies. He has been involved in more than 50 clinical trials with more than 25 drugs across multiple therapeutic areas including cardiovascular, metabolic, neurology, oncology, infectious diseases, rheumatology, ophthalmology and several rare diseases, in the U.S. and globally. Dr. Hughes has also played a key role in the submission of multiple NDA/MAA applications. Most recently he served as the Chief Medical Officer of Organovo where he led the non-clinical and clinical development teams developing bioprinted tissues for treatment of hepatic and renal diseases. Prior to that he was Chief Clinical Development Officer at Ionis Pharmaceuticals, where he led a team that managed the global clinical development of multiple drugs across several therapeutic areas. He has also held positions at Biogen Idec, CSL Behring and Sanofi. Dr. Hughes is Board Certified in Pharmaceutical Medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial College Business School.
Daniel HwangAccounting Supervisor Priya KarmaliVP, Technology Innovation and Development Bio
VP, Technology Innovation and Development
Priya Karmali is Vice President of Technology Innovation and Development at Arcturus Therapeutics. In her current position, she is responsible for research and development efforts for LUNAR® technology, Arcturus’ lipid mediated nucleic acid delivery system. Priya has over 20 years of experience in the field of lipid mediated nucleic acid delivery from discovery to development and has led drug product development of multiple RNA based therapeutics that are currently in various phases of clinical trials. Prior to Arcturus, Priya led formulation and drug product development of multiple miRNA candidates at Regulus Therapeutics. Prior to Regulus, Priya held positions of increasing responsibility at Nitto Denko where she led formulation development efforts for ND-L02-s0201, a Vitamin A targeted siRNA lipid nanoparticle, currently in various stages of clinical trials for hepatic and Idiopathic Pulmonary fibrosis. Priya received her PhD in Chemistry from the Indian Institute of Chemical Technology, India where her doctoral research was focused on development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She pursued her postdoctoral research at Sanford-Burnham-Preby’s-Medical Discovery Institute, La Jolla, CA focusing on developing targeted nanoparticles for drug delivery. Priya is an author and co-inventor on over 40 publications and patents.
Jae Heon (Jay) KimResearch Associate I, Formulation Development Kristen KuakiniResearch Associate II Greg KubczakAssociate Director, Technical Services KC KummerfeldVice President, Finance & Corporate Controller Bio
Vice President, Finance & Corporate Controller
K.C. Kummerfeld, CPA has over 20 years of financial executive experience working in fast paced companies within the Biotechnology and Technology industries. Prior to Arcturus, Mr. Kummerfeld worked in various Silicon Valley Technology Companies including Openwave Systems, Inc. where he held the role of Corporate Controller and helped establish the key accounting and finance controls necessary to grow the public company to over $400 million annual revenues and over 2,500 employees. Mr. Kummerfeld also worked for the accounting firm of KPMG after graduating from San Diego State University.
Yi KuoResearch Associate II Robin LeeSenior Research Associate, Analytical Development Angel LeuSenior Research Associate, Frontier Science Pattraranee (Patty) LimphongAssociate Director, Drug Discovery Maher AlayyoubiScientist II, RNA Process Development Dr. Magda MarquetDirector of the Board Bio
Dr. Magda Marquet
Director of the Board
Dr. Marquet is the co-Founder of ALMA Life Sciences, LLC, an early stage investment firm focusing on the creation and growth of innovative healthcare companies with an overall focus on prevention. She is also the co-Founder of AltheaDx, a commercial stage precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression.
Dr. Marquet co-founded Althea Technologies in 1998 and led the company to the successful acquisition by Ajinomoto, a global Japanese company, leader in amino acid technology. During her tenure at Althea Technologies, Dr. Marquet had full P&L responsibility and built an organization with R&D and international commercial capabilities. Prior to starting Althea Technologies, Dr. Marquet held several positions in product development and pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals.
She currently serves on the following Boards: Pfenex (PFNX) where she is a member of the Governance and Nomination Committee and Arcturus Therapeutics (ARCT) where is the Chairman of the Compensation Committee and a member of the Audit Committee. She also serves on the Board on several private companies such as Senté. As a former founder and CEO, Dr Marquet provides the Board with operational, fund raising expertise including venture, private equity and venture debt. She also brings expertise in M&A, global commercial development and regulatory strategies. She has a passion for building a winning culture of innovation and strategic growth.
She holds a Ph.D. in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous prestigious awards throughout her career including the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category, the Athena Pinnacle award, the Director of the Year award (Corporate Governance) from the Corporate Directors Forum and has been inducted into the CONNECT Entrepreneur Hall of Fame.
Daiki MatsudaAssociate Director, Frontier Science Rajesh MukthavaramScientist II, Formulation Development Michelle NguyenSenior Research Associate, Analytical Development Jocelyn TabaldoAdministrative Assistant Suezanne ParkerVice President, Translational Biology Bio
Vice President, Translational Biology
Suezanne Parker has 25+ years of pharmaceutical industry experience in preclinical drug development from research/discovery through global marketing approvals with several paradigms (gene therapy, small molecules, biologics) in multiple therapeutic areas (Vaccines, Infectious Disease, Neurology, Immunology, Oncology, Ophthalmology, Rare Disease). During her career she has lead Discovery Research, Pharmacology, Toxicology/Pathology, Toxicological Risk Assessment, PK/ADME, Bioanalytical, and Nonclinical Regulatory Submissions Writing Departments. She joined Arcturus Therapeutics as the VP of Translational Biology in August 2018 where she is responsible for the development of Arcturus’s novel RNA medicine platforms. Prior to Arcturus, she was the Senior Director of Toxicology at Shire where her team supported the nonclinical efforts for the marketing applications for Xiidra®, Vyvanse®, and Takhzyro®, for Dry Eye Disease, Binge Eating Disorder, and the first mAb approved for hereditary angioedema, respectively. She also provided nonclinical guidance for Shire’s first Gene Therapy (AAV) programs. Prior to joining Shire, Suezanne was at Biogen Idec Pharmaceuticals where she was the site head for Nonclinical Development (Toxicology, Bioanalytical, PK/DM, and the Animal Facility) at the San Diego Campus. As the Director of Preclinical Safety at Biogen Idec, she supported marketed products for MS (Avonex®, Tysabri®, and Fampridine®) as well as developmental candidates from research/discovery through Late Stage Development. While at Biogen Idec, Suezanne was the preclinical safety lead for Rituxan®, Tecfidera®, Plegridy®, and Zinbryta® for multiple sclerosis. Suezanne started her career in Industry at Vical Inc. in San Diego CA where she was responsible for the management of Pharmacology, Preclinical Safety and the Animal Facility. At Vical, she led the preclinical efforts for some of the first in human trials for plasmid DNA therapy. Suezanne completed her postdoctoral studies at Scripps Clinic and Research Foundation studying the viral pathogenesis of CNS disease. She received her PhD in Biochemistry and Molecular Biology from the University of California, Santa Barbara.
Paula HartmanSr. Research Associate, RNA Sciences Joseph E. PaynePresident & CEO, Director of the Board Bio
Joseph E. Payne
President & CEO, Director of the Board
Joseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Carlos Perez-GarciaSenior Scientist, Translational Biology Edgardo Pica Research Associate I, Analytical Development Kumar RajappanPrincipal Scientist, Chemistry Janet ReedExecutive Assistant Josie RiveraResearch Associate I Neda SafarzadehDirector, Head of Investor Relations/Public Relations and Marketing Joseph RobertsAssistant Controller Scott RobertsAssociate Director, CMC Marciano SabladSenior Manager, Translational Biology Hazel SantosAccounts Payable Specialist Andrew SassineChief Financial Officer Bio
Chief Financial Officer
Andy Sassine is currently, and has been since January 2019, the Chief Financial Officer at Arcturus Therapeutics. He also serves on the Board of Directors of Nasdaq listed ICAD Inc. ICAD Inc. is a leading provider of advanced image analysis, workflow solutions and radiation therapy for early detection and treatment of cancer. Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. Between 2005 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors from 2009 to 2018. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.
Kyle ScurlockSenior Accountant Kevin SkolSenior Vice President, Business Development & Alliance Management Bio
Senior Vice President, Business Development & Alliance Management
Kevin Skol has nearly 20 years of experience in the pharmaceutical industry, primarily in corporate development, alliance management, strategy and licensing roles. He previously worked at RNA target-based companies Ionis Pharmaceuticals and Digital Gene Technologies and at specialty pharmaceutical companies Elan Corporation and Valeant Pharmaceuticals. At Ionis he led business development and licensing efforts that resulted in major pharmaceutical partnerships with Astra Zeneca, Roche, Janssen, Novartis and Biogen. The combined transaction value of collaborative agreements and partnerships which he led throughout his career is estimated at over $2 billion. Mr. Skol graduated with a B.A. from Yale University and has an MBA from Harvard Business School.
Ji Young SukAssociate Director, Translational Biology Kiyoshi TachikawaSenior Research Fellow, Frontier Science Wendy TaylorSenior Director, Program Management Ramon Diaz TrellesSenior Scientist, Frontier Science Jerel VegaManager, Formulation Production Andres Valderrama Scientist II, Frontier Science Lishuang (Lily) XuSenior Research Associate, Drug Discovery Rodrigo YelinSenior Program Manager Hyojung HongResearch Assistant, Formulation Development Cristiano SacchettiScientist II, Translational Biology Tyler RaymerFacilities Manager Abraham GomezResearch Associate II, Translational Biology Mario OrnelasQuality Manager, Quality & Regulatory Claine SnowSr. IP & Transactions Counsel Brenda ClementeSenior Research Associate, Formulation Development Rob LopezFacilities-Shipping & Receiving Emily ChaoResearch Associate I, Frontier Science Hannah HuynhLab Support Technician Mukunda KrishnaSenior Engineer, Technical Transfer Yi-Yu LinScientist II, Formulation Development Alana MontoyaSenior Research Associate, RNA Production Lisa Kieweg-ThompsonResearch Associate II, RNA Production Phuong-Danh TranResearch Associate I, Formulation Development Alex DailyPurchasing Manager Gloria ZhangResearch Associate I Sean SullivanExecutive Director, Process Development Pamela ReschExecutive Director, Quality and Regulatory Affairs Nadja El-MecharrafieResearch Associate II, Frontier Science Linda QuirinoResearch Associate II, Translational Biology Tim LugerResearch Associate II, RNA Process Development Cristine OhlsonContracts Administrator/Paralegal Yurong GuoSenior Manager, Analytical Development and QC Tyler SpencerSenior Financial Analyst Simone Ward Life Sciences Patent Attorney Howard YuScientist II, Analytical Development Natasha BowmanVice President, Head of Human Resources Bio
Vice President, Head of Human Resources
Natasha O. Bowman, has more than 25 years of in the field of Human Resources with robust industry and leadership experience in the pharmaceutical, medical device, manufacturing and public sectors. Ms. Bowman most recently was the Senior Vice President of Human Resources at Synthetic Genomics for over 7 years where she served as a strategic adviser providing guidance on all HR related matters to the CEO, Board of Directors, and other members of the executive team. She previously held positions in start-up, mid-size, and Fortune 500 companies including Althea Technologies, ACADIA Pharmaceuticals and Pfizer Inc. where she played a key role in the start-up, growth, and mergers & acquisitions of those organizations. Ms. Bowman received a B.S in Business Management from San Diego State University. She was named as one of San Diego’s 500 Most Influential Business Leaders by the San Diego Business Journal in 2018, 2019, and 2020. She is on the Board of Directors for the non-profit organizations San Diego Girl Scouts, San Diego HR Forum, Lakeside River Park Conservancy, and Friends of Music.
Juthamart BradyResearch Associate, Drug Discovery Noa ScottHuman Resources Coordinator Yihua Pei Scientist I, Formulation Development Lance KurataChief Legal Officer Bio
Chief Legal Officer
Lance Kurata has served as the Chief Legal Officer of Arcturus Therapeutics since August 2020. Prior to Arcturus, from 2006 to 2020, Mr. Kurata was a partner at Mintz Levin and Chair of the West Coast Technology Transactions Practice. From 2002 to 2006, he was a partner at Fish & Richardson, where he was a member of the corporate group and nationwide head of the technology transactions practice. From 1996 until 2002, Mr. Kurata practiced corporate law at Brobeck Phleger & Harrison, specializing in strategic collaborations, public and private financings, mergers and acquisitions and corporate governance. Mr. Kurata is licensed to practice law in the State of California. He received his Juris Doctor (JD) degree from Stanford Law School and was an editor of Stanford Law Review.
Kelly Lindert Senior Vice President, Head of Vaccine Clinical Development Bio
Senior Vice President, Head of Vaccine Clinical Development
Dr. Kelly Lindert is the Senior Vice president of vaccines clinical development. She has 20 years of experience in pharma and biotech industries and spent nearly ten years working on vaccines, including pandemic vaccines, at Acambis and Novartis. At Novartis she rose to serve as Head of Development and led the team for the approval of Fluad and the first quadrivalent cell-based influenza vaccine in the US. More recently she worked at Moderna Therapeutics. She received her medical degree at the University of Chicago and trained in Urology at Stanford.
Diana CorreaResearch Assistant, Analytical Development Henry Shafron Research Assistant, Analytical Development Reggie Hooks Director, Clinical Trials Management
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA chemistry and delivery technologies.
September 8, 2020 Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences read more
September 4, 2020 Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate read more
August 18, 2020 Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health read more